Table Graph
      published meta-analysis   sensitivity analysis   studies

casirivimab/imdevimab (Ronapreve) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias Emergency room visit or hospitalizationdetailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.12 [0.01; 2.35] 0.12[0.01; 2.35]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 202110%1,505NAnot evaluable deathsdetailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 1.00 [0.14; 7.08] 1.00[0.14; 7.08]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 202110%2,617NAnot evaluable symptomatic Covid-19detailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.17 [0.09; 0.33] 0.17[0.09; 0.33]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 202110%1,505NAnot evaluable serious adverse eventsdetailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 2.97 [1.75; 5.03] 2.97[1.75; 5.03]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 202110%2,617NAnot evaluable adverse eventsdetailed resultsCov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 0.62 [0.52; 0.74] 0.62[0.52; 0.74]Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 202110%2,617NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-11-04 22:30 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 771 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons